UCB (OTCMKTS:UCBJF) Sets New 1-Year High - What's Next?

Key Points

• UCB SA's share price reached a new 52-week high of $305.89 during trading, closing at $302.79, up from a previous close of $293.00.
• Analyst ratings remain positive, with both Deutsche Bank and Morgan Stanley issuing "buy" or "overweight" ratings, contributing to a consensus rating of "Buy."
• The company's stock has seen a 4.1% increase, with key financial indicators showing a healthy debt-to-equity ratio of 0.33 and a current ratio of 1.19.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $305.89 and last traded at $302.79, with a volume of 116 shares changing hands. The stock had previously closed at $293.00.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on UCBJF. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of UCB in a report on Monday. Morgan Stanley reiterated an "overweight" rating on shares of UCB in a research note on Monday, September 8th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy".

UCB Stock Up 4.1%

The stock's 50-day simple moving average is $241.00 and its 200 day simple moving average is $200.77. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.